Multi Epitope-Based Vaccine Design for Protection Against Mycobacterium tuberculosis and SARS-CoV-2 Coinfection.

Q2 Biochemistry, Genetics and Molecular Biology Advances and Applications in Bioinformatics and Chemistry Pub Date : 2022-08-02 eCollection Date: 2022-01-01 DOI:10.2147/AABC.S366431

Dian Ayu Eka Pitaloka, Afifah Izzati, Siti Rafa Amirah, Luqman Abdan Syakuran

{"title":"Multi Epitope-Based Vaccine Design for Protection Against Mycobacterium tuberculosis and SARS-CoV-2 Coinfection.","authors":"Dian Ayu Eka Pitaloka, Afifah Izzati, Siti Rafa Amirah, Luqman Abdan Syakuran","doi":"10.2147/AABC.S366431","DOIUrl":null,"url":null,"abstract":"Background: A prophylactic and immunotherapeutic vaccine for Mycobacterium tuberculosis (MTB) and SARS-CoV-2 coinfection needs to be developed for a proactive and effective therapeutic approach. Therefore, this study aims to use immunoinformatics to design a multi-epitope vaccine for protection against MTB and SARS-CoV-2 coinfection.Methods: The bioinformatic techniques were used to screen and construct potential epitopes from outer membrane protein A Rv0899 of MTB and spike glycoprotein of SARS-CoV-2 for B and T cells. The antigenicity, allergenicity, and several physiochemical properties of the developed multi-epitope vaccination were then evaluated. Additionally, molecular docking and normal mode analysis (NMA) were utilized in evaluating the vaccine's immunogenicity and complex stability.Results: Selected proteins and predicted epitopes suggest that the vaccine prediction can be helpful in the protection against both SARS-CoV-2 and MTB coinfection. Through docking molecular and NMA, the vaccine-TLR4 protein interaction was predicted to be efficient with a high level of IgG, T-helper cells, T-cytotoxic cells, andIFN-γ.Conclusion: This epitope-based vaccine is a potentially attractive tool for SARS-CoV-2 and MTB coinfection vaccine development.","PeriodicalId":53584,"journal":{"name":"Advances and Applications in Bioinformatics and Chemistry","volume":" ","pages":"43-57"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/df/aabc-15-43.PMC9356608.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances and Applications in Bioinformatics and Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/AABC.S366431","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 4

Abstract

Background: A prophylactic and immunotherapeutic vaccine for Mycobacterium tuberculosis (MTB) and SARS-CoV-2 coinfection needs to be developed for a proactive and effective therapeutic approach. Therefore, this study aims to use immunoinformatics to design a multi-epitope vaccine for protection against MTB and SARS-CoV-2 coinfection.

Methods: The bioinformatic techniques were used to screen and construct potential epitopes from outer membrane protein A Rv0899 of MTB and spike glycoprotein of SARS-CoV-2 for B and T cells. The antigenicity, allergenicity, and several physiochemical properties of the developed multi-epitope vaccination were then evaluated. Additionally, molecular docking and normal mode analysis (NMA) were utilized in evaluating the vaccine's immunogenicity and complex stability.

Results: Selected proteins and predicted epitopes suggest that the vaccine prediction can be helpful in the protection against both SARS-CoV-2 and MTB coinfection. Through docking molecular and NMA, the vaccine-TLR4 protein interaction was predicted to be efficient with a high level of IgG, T-helper cells, T-cytotoxic cells, andIFN-γ.

Conclusion: This epitope-based vaccine is a potentially attractive tool for SARS-CoV-2 and MTB coinfection vaccine development.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

基于多表位的预防结核分枝杆菌和SARS-CoV-2联合感染疫苗设计

背景:需要开发针对结核分枝杆菌(MTB)和SARS-CoV-2合并感染的预防性和免疫治疗性疫苗，以获得积极有效的治疗方法。因此，本研究旨在利用免疫信息学技术设计一种多表位疫苗，以预防MTB和SARS-CoV-2合并感染。方法:利用生物信息学技术筛选结核分枝杆菌外膜蛋白A Rv0899和SARS-CoV-2刺突糖蛋白，构建B细胞和T细胞的潜在表位。然后评估了所开发的多表位疫苗的抗原性、过敏原性和几种物理化学性质。此外，利用分子对接和正常模式分析(NMA)评价疫苗的免疫原性和复合物稳定性。结果:选择的蛋白和预测的表位表明，疫苗预测可以帮助预防SARS-CoV-2和MTB合并感染。通过对接分子和NMA，预测疫苗- tlr4蛋白相互作用对高水平的IgG、t辅助细胞、t细胞毒性细胞和difn -γ有效。结论:该抗原表位疫苗是SARS-CoV-2和MTB联合感染疫苗开发的潜在有效工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Advances and Applications in Bioinformatics and Chemistry Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (miscellaneous)

CiteScore

6.50

自引率

0.00%

发文量

审稿时长

16 weeks